Replicable attenuated vaccinia virus with or without expression of human FLT3L or GM-CSF with thymidine kinase deletion for cancer immunotherapy

摘要

PROBLEM TO BE SOLVED: To malignant tumors are inherently resistant to conventional treatment methods and present a serious therapeutic problem. Immunotherapy has become an evolving field of study and has become an additional option for the treatment of certain types of cancer. The present invention relates to the fields of oncology, virology, and immunotherapy. More specifically, of a replicable attenuated vaccinia virus with or without expression of Flt3L or GM-CSF, with or without deletion of poxvirus, in particular thymidine kinase (VC - TK-). For use as oncolytic or immunotherapy. The poxviruses mentioned above can also be used in combination with immune checkpoint blockers. [Selection diagram] Fig. 1